Literature DB >> 10943643

Outcome measures in asthma.

N C Barnes1.   

Abstract

Mesh：

Year:  2000        PMID： 10943643      PMCID： PMC1765944          DOI： 10.1136/thorax.55.suppl_1.s70

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  11 in total

1.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

2.  Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

Authors:  A E Tattersfield; D S Postma; P J Barnes; K Svensson; C A Bauer; P M O'Byrne; C G Löfdahl; R A Pauwels; A Ullman
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

3.  Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group.

Authors:  J K Sont; L N Willems; E H Bel; J H van Krieken; J P Vandenbroucke; P J Sterk
Journal:  Am J Respir Crit Care Med       Date:  1999-04       Impact factor: 21.405

4.  Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma.

Authors:  D Ukena; U Harnest; R Sakalauskas; P Magyar; N Vetter; H Steffen; S Leichtl; F Rathgeb; A Keller; V W Steinijans
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

5.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

Authors:  D J Evans; D A Taylor; O Zetterstrom; K F Chung; B J O'Connor; P J Barnes
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

6.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

Authors:  R A Pauwels; C G Löfdahl; D S Postma; A E Tattersfield; P O'Byrne; P J Barnes; A Ullman
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

7.  Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group.

Authors:  K Malmstrom; G Rodriguez-Gomez; J Guerra; C Villaran; A Piñeiro; L X Wei; B C Seidenberg; T F Reiss
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  Differences between asthma exacerbations and poor asthma control.

Authors:  H Reddel; S Ware; G Marks; C Salome; C Jenkins; A Woolcock
Journal:  Lancet       Date:  1999-01-30       Impact factor: 79.321

9.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.

Authors:  A P Greening; P W Ind; M Northfield; G Shaw
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

10.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.

Authors:  A Woolcock; B Lundback; N Ringdal; L A Jacques
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405
View more
  3 in total

1.  Treatment compliance, passive smoking, and asthma control: a three year cohort study.

Authors:  D Soussan; R Liard; M Zureik; D Touron; Y Rogeaux; F Neukirch
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

2.  AKL1, a botanical mixture for the treatment of asthma: a randomised, double-blind, placebo-controlled, cross-over study.

Authors:  Michael Thomas; Jane Sheran; Natalie Smith; Sofia Fonseca; Amanda J Lee
Journal:  BMC Pulm Med       Date:  2007-03-20       Impact factor: 3.317

3.  Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.

Authors:  Mike Thomas; David Price; Henry Chrystyn; Andrew Lloyd; Angela E Williams; Julie von Ziegenweidt
Journal:  BMC Pulm Med       Date:  2009-01-02       Impact factor: 3.317
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.